Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Use with caution in patients with G6PD deficiency (see warnings and interactions) High-risk patients (for whom high-dose ciprofloxacin use is expected to increase risks)Ciprofloxacin (fluoroquinolone) Consumption by patients with high-risk g6PD deficiency (see warnings and interactions) Concomitant use with high-dose ciprofloxacinCiprofloxacin, however, does not have the same risk of severe drug interactions with other quinolones. Therefore, patients should be advised to consult their healthcare provider when using these quinolones, especially if they have a high risk of severe interactions. Ciprofloxacin should only be used after careful consideration by the doctor as it may be an indication that the quinolone may be causing serious side effects.
Ciprofloxacin should not be used in patients with severe liver disease or glucose control difficulties. Ciprofloxacin should not be given to patients with hepatic impairment because it may lead to a serious blood disorders. Ciprofloxacin should not be used in patients with QT interval prolongation or torsades de pointes or its absence should not be used as a substitute to liver function tests. Ciprofloxacin should be used with caution in patients with pre-existing aortic aneurysm or dissection. Ciprofloxacin should not be used in pediatric patients because it may cause fatal personal data protection (i.e. persistent vomiting, diarrhea, loss of appetite, loss of consciousness, foreign body sensation, skin irritation, respiratory failure, mycobacterial infection, urinary tract infections, and other side effects) in these patients. Ciprofloxacin should not be used in patients who previously hadautions or complications associated with these medications (e.g. renal impairment, pre-existing QT prolongation, uncorrected hypokalaemia/hypomagnesaemia). Avoid use by patients with pre-existing aortic aneurysm or dissection. Ciprofloxacin should be used with caution in these patients because it may lead to a serious blood disorders. Dosage and administration should be adjusted according to the patient's blood pressure and other factors as determined by the doctor.
Background:Ciprofloxacin is a synthetic antibiotic that is widely used in both human and veterinary medicine to treat a range of bacterial infections and can be used to prevent or treat infections due to Gram-negative bacteria. The goal of this work was to evaluate the clinical significance of the bactericidal action of ciprofloxacin against a range of Gram-negative bacteria, includingPseudomonas aeruginosa(NuMA) andStaphylococcus aureus(S. aureus). This study was designed to determine whetherP. aeruginosacould be an alternative to ciprofloxacin due to its broader spectrum of activity against Gram-negative bacteria, as compared with ciprofloxacin.
Methods:Twenty patients (22 men and 20 women) withwere included in this study. A total of 35 ciprofloxacin-resistant (CR) and 35 ciprofloxacin-sensitive (CR-S) isolates were selected for further analysis, and ciprofloxacin-resistant isolates were included in the study. Clinical outcomes of patients were recorded, and clinical and bacteriological outcomes were evaluated. The clinical data were analyzed by using the chi-square test, the paired Student’s t test, the Mann-Whitney test, the Kruskal-Wallis test, and the Mann-Whitney U test. All statistical analyses were performed with SPSS Statistics software program, version 25.
Conclusion:This study showed that ciprofloxacin could be an alternative to ciprofloxacin due to its broader spectrum of activity against Gram-negative bacteria, as compared to ciprofloxacin.
The incidence of infections due to gram-negative bacteria remains an important concern for both healthcare providers and public health workers. Currently, there are several antibiotic agents that are effective against gram-negative bacteria such asEscherichia colior(penicillinase), and these antibiotics are commonly used in clinical practice to treat infections due to Gram-negative bacteria. The effectiveness of ciprofloxacin againstis not well-established.
In this study, we evaluated the bactericidal action of ciprofloxacin against Gram-negative bacteria, including, againstthat could be a treatment option for these infections. We also characterized the clinical outcomes of the ciprofloxacin-resistantstrains in these patients.
This study was designed to evaluate the bactericidal action of ciprofloxacin against Gram-negative bacteria, including
Twenty patients (22 men and 20 women) with a history of infection due to, a resistantE. colistrain, or, a non-susceptiblestrain, and, a susceptiblestrain, were included in the study. Patients received ciprofloxacin (2.5 or 500 mg/kg/day) or ciprofloxacin-susceptiblestrain, and were admitted to the intensive care unit, depending on their clinical status. The patients were admitted for at least 3 days and received intravenous (IV) ciprofloxacin (500 mg/kg) or ciprofloxacin-susceptiblestrain. All patients were monitored at the time of discharge and were hospitalized until they were discharged after they were stable. The ciprofloxacin-susceptible
Ophthalmic ciprofloxacin comes as a solution (liquid) to apply to the eyes. Ciprofloxacin ophthalmic solution is usually used often, between once every 15 minutes to once every four hours while awake for seven to 14 days or longer. Ciprofloxacin ophthalmic ointment is usually applied three times a day for two days and then twice a day for five days. Use ciprofloxacin ophthalmic at around the same time every day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Use ciprofloxacin ophthalmic exactly as directed. Do not use it more often than prescribed by your doctor.
You should expect your symptoms to improve during your treatment. Call your doctor if your symptoms do not go away or get worse, or if you develop other problems with your eyes during your treatment.
Use ophthalmic ciprofloxacin until you finish the prescription, even if you feel better. If you stop using ophthalmic ciprofloxacin too soon, your infection may not be completely cured and the bacteria may become resistant to antibiotics.
To instill the eye drops, follow these steps:
Wash your hands thoroughly with soap and water.
Check the dropper tip to make sure that it is not chipped or cracked.
Avoid touching the dropper tip against your eye or anything else; eyedrops and droppers must be kept clean.
While tilting your head back, pull down the lower lid of your eye with your index finger to form a pocket.
Hold the dropper (tip down) with the other hand, as close to the eye as possible without touching it.
Brace the remaining fingers of that hand against your face.
While looking up, gently squeeze the dropper soa single drop falls into the pocket made by the lower eyelid. Remove your index finger from the lower eyelid.
Close your eye for two to three minutes and tip your head down as though looking at the floor. Try not to blink or squeeze your eyelids.
Place a finger on the tear duct and apply gentle pressure.
Wipe any excess liquid from your face with a tissue.
If you are to use more than one drop in the same eye, wait at least five minutes before instilling the next drop.
Replace and tighten the cap on the dropper bottle. Do not wipe or rinse the dropper tip.
Wash your hands to remove any medication.
To apply the eye ointment, follow these instructions:
Avoid touching the tip of the tube against your eye or anything else; the tube tip must be kept clean.
Holding the tube between your thumb and forefinger, place it as near to your eyelid as possible without touching it.
Tilt your head backward slightly.
With your index finger, pull the lower eyelid down to form a pocket.
Squeeze a 1/2-inch (1.25cm) ribbon of ointment into the pocket made by the lower eyelid.
Blink your eye slowly; then gently close your eye for one to two minutes.
With a tissue, wipe any excess ointment from the eyelids and lashes. With another clean tissue, wipe the tip of the tube clean.
Replace and tighten the cap right away.
You should expect your symptoms to improve within 5 days of stopping treatment; however, improvement usually occurs a few weeks later.
What is ciprofloxacin? Ciprofloxacin, also known as ciprofloxacin, is a powerful antibiotic that fights bacteria that cause various infections in the body.Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Use on animals only.ciprofloxacin
Bacterial vaginosis (BV) may occur in patients taking ciprofloxacin with other medications which may cause side effects, although these side effects are usually mild and may go away during treatment with lower dose therapy. Gastrointestinal symptoms, such pain, disturbances of taste, malaise, bloating, and metallic taste are few and may occur during treatment with lower dose therapy. Improvements in BV and BV-related symptoms have been clinically proven in numerous clinical studies, both in patients on maintenance therapy and patients with untreated infection. In patients with untreated infection, BV-related symptomatic inflammation and bleeding are common. Indigestion, dizziness, and blurred vision, especially in elderly patients, may occur. In patients with untreated BV, treatment with lower dose therapy may lead to improvement in BV-related symptoms. Some BV-related side effects may disappear after 4 to 8 weeks of treatment with lower dose therapy. Most side effects are mild and do not require treatment. However, if the side effects are persistent, or are bothersome, please consult your doctor.
BV treatment should be considered in patients with pre-existing pre-existing conditions, since high concentrations of ciprofloxacin may be detected in plasma. If vaginosis occurs, please inform your doctor. BV treatment should not be stopped suddenly and please consult your doctor. BV-related symptoms, such as dizziness, drowsiness, irritability, agitation, depression, and/or anxiety, may persist even after treatment with lower dose therapy. BV-related therapy should not be stopped suddenly and please consult your doctor. BV-related symptoms, such as dizziness, drowsiness, irritability, agitation, depression, and/or anxiety, may remain even after treatment with lower dose therapy. Please consult your doctor.
Some medications may have interactions with ciprofloxacin. Please inform your doctor if you experience any adverse reactions to ciprofloxacin, its salts, foods, preservatives or dyes. These may be changed or removed w/o notice.
Stade de France Pharmacy